The best evidence on isotretinoin and mental health does not show that treatment raises depression, suicide, or other psychiatric risks across populations. It cannot rule out a rare reaction in one person. Acne itself can affect mental health, which makes cause and effect hard to separate. Share your mental health history before treatment and agree on monitoring. Report any new or worsening mood, thoughts, sleep, or behaviour to your prescribing team promptly.
Accutane is a familiar brand name for oral isotretinoin, a prescription acne medicine. This article addresses mental health risk, not whether isotretinoin suits your acne. For that decision, read when clinicians consider isotretinoin.
Isotretinoin and mental health: the strongest pooled evidence
Tan and colleagues reviewed 25 studies and pooled 24 in a 2024 JAMA Dermatology meta-analysis. The studies included 1,625,891 participants. At one year, pooled risks were below 0.5% for completed suicide, suicide attempts, suicidal thoughts, and self-harm. The pooled depression risk was 3.83%, with a 95% confidence interval from 2.45% to 5.93%.
Isotretinoin was not associated with all psychiatric disorders compared with nonuse. The risk ratio was 1.08, with a 95% confidence interval from 0.99 to 1.19. That range is compatible with little difference and does not prove equal risk. The researchers found fewer suicide attempts two to four years after treatment, but that result does not show the medicine prevents suicide.
These are group averages. The depression estimate varied widely across studies, with an I² of 77%. Each pooled suicide or self-harm estimate also came from only two to eight studies. A reassuring average can still miss an uncommon reaction in a susceptible person.
Why the studies cannot prove zero individual risk
Most evidence about serious psychiatric outcomes is observational. Large randomised trials designed to detect rare harms over several years would be difficult and costly. So observational data carry most of the answer.
- Acne severity can confuse the comparison. People offered isotretinoin often have more severe or persistent acne. NICE recognises that acne of any severity can cause psychological distress.
- Prescriber selection can bias results. Clinicians may avoid isotretinoin when they judge psychiatric risk to be high. That could make treated groups look safer.
- Closer observation can shift results the other way. Regular visits may detect symptoms that routine records miss in other groups.
- Diagnosis codes can miss low mood, suicidal thoughts, or symptoms handled outside the recorded health system.
The comparison group changes the result. Paljarvi and colleagues studied 30,866 isotretinoin users aged 12 to 27 in 2022. After matching, their odds of any new neuropsychiatric outcome were lower than with oral antibiotics. The odds ratio was 0.80. Results were similar to topical treatment and to acne without a recorded prescription.
A second large cohort gives a more mixed picture. Kridin and Ludwig matched 75,708 isotretinoin users with 75,708 oral-antibiotic users in 2023. Major depression and suicide-attempt risks were similar. Recorded suicidal ideation was higher with isotretinoin, with a hazard ratio of 1.41. Retrospective records cannot show whether the medicine caused that difference.
Newer safety-report data answer a different question. Nie and colleagues examined 19,412 psychiatric event reports linked to isotretinoin in a 2025 study. They found reporting signals across mood disorders, self-injury, anxiety, bipolar disorder, and psychosis. That design can flag events to monitor. It cannot tell how common they are or whether isotretinoin caused them.
What current guidance asks clinicians to do
Population findings have not removed the need for monitoring. The UK MHRA’s January 2026 measures require a mental health assessment before prescribing. They also call for a patient-reported measure and mental health review at every follow-up.
The British Association of Dermatologists says a questionnaire supports assessment but doesn’t diagnose a condition. No questionnaire is validated specifically for isotretinoin treatment. A high score is not an automatic bar, especially when acne contributes to the distress. It should lead to clinical assessment and a shared decision.
NICE’s 2026 guideline also calls for regular psychological review. It says severe mental health problems need urgent medical advice. That action depends on the symptoms, not on proving isotretinoin caused them.
Current US prescribing information also tells clinicians to assess depression, psychosis, suicidal thoughts, and aggressive behaviour before and during treatment. US iPLEDGE rules address pregnancy risk; they do not replace mental health review.
A past mental health condition does not automatically rule out treatment. It does change the monitoring plan. Tell the prescriber about past depression, anxiety, bipolar disorder, self-harm, eating disorders, and current mental health care.
A decision table for mood or behaviour changes
| What you notice | What it could mean | Useful next step | What it cannot prove |
|---|---|---|---|
| Low mood or anxiety before the first dose | Acne, an existing condition, sleep loss, or another stressor may contribute. | Tell the prescriber and record your baseline symptoms. | It does not predict with certainty how treatment will affect you. |
| New or worsening low mood, panic, irritability, insomnia, or withdrawal | The medicine could contribute. Acne, physical side effects, and life events can also matter. | Contact the prescribing team promptly. Give the start date, timing, severity, and effect on daily life. | Timing alone does not establish causation. |
| A friend notices a behaviour change you missed | An outside view may catch withdrawal, agitation, or unusual behaviour. | Ask for concrete examples and share them with your clinician. | A friend’s observation is not a diagnosis. |
| Self-harm or suicidal thoughts, hallucinations, psychosis, or immediate danger | This is a severe mental health event, whatever the cause. | Seek urgent local emergency or mental health care now, then alert the prescribing team. | You do not need to establish the cause before getting help. |
| Mood improves as acne clears | Relief from painful or distressing acne may help wellbeing. | Keep following the agreed monitoring plan. | Improvement does not prove a direct protective drug effect. |
Build the monitoring plan before the first dose
Ask who will review your baseline and how often follow-up will occur. Confirm whom to contact between visits. If another clinician manages your mental health, ask how the teams will share relevant changes.
During treatment, describe changes with dates and concrete effects. “I stopped seeing friends and slept four hours nightly for six days” is more useful than “I feel off.” A trusted person can also watch for changes you may not notice.
Do not use a single questionnaire score to diagnose yourself or settle a prescription decision. If symptoms are worsening, contact the prescribing or mental health team rather than waiting for the next routine visit. If you may harm yourself or cannot stay safe, use local emergency care now.
Mental health is only one part of isotretinoin safety
Isotretinoin is contraindicated in pregnancy because it can cause severe fetal harm. The US uses iPLEDGE, while the UK uses an MHRA Pregnancy Prevention Programme. As of 28 October 2026, FDA changes planned for 15 November were not yet in force. Follow the current programme given by your prescriber.
The current US label also calls for lipid and liver testing. It lists vitamin A supplements and tetracycline antibiotics as interactions and includes blood-donation precautions. UK monitoring also asks about sexual function concerns. These checks answer different risks; a normal mood questionnaire cannot replace them. The isotretinoin blood-test guide explains what laboratory monitoring can and cannot show.
Dry lips, skin, and eyes are among the common labelled effects. Paljarvi’s team warned that physical side effects may also affect mental health. The month-by-month isotretinoin guide sets realistic expectations, while the urgent side-effect guide separates common problems from warning signs.
Questions to take to the prescriber
- What will you record as my mental health baseline?
- Which mood, sleep, or behaviour changes need same-day contact?
- Who should I contact between scheduled visits?
- How will my GP or mental health clinician be involved?
- What is the plan if acne improves but my mental health worsens?
Oscar Nascimento
Editorial writer, GlowUp Face
Oscar writes about evidence-based skin care, healthcare, looksmaxxing, and the social and economic research surrounding appearance.
Full profile and all articles →
